ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis Takes Stake In Stem Cell Firm

by Ann M. Thayer
August 25, 2014 | APPEARED IN VOLUME 92, ISSUE 34

Novartis has agreed to invest in, and possibly buy, Gamida Cell, an Israeli company developing stem cell therapies. Novartis will pay $35 million for a 15% stake in Gamida and an option to buy the company if it meets certain clinical milestones by the first half of 2016. If Novartis exercises the option, it will pay another $165 million and up to $435 million in milestone payments. Gamida has a treatment for hematological malignancies, such as leukemia and lymphoma, in early-stage clinical trials.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment